"Antibodies, Neoplasm" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Immunoglobulins induced by antigens specific for tumors other than the normally occurring HISTOCOMPATIBILITY ANTIGENS.
| Descriptor ID |
D000912
|
| MeSH Number(s) |
D12.776.124.486.485.114.240 D12.776.124.790.651.114.240 D12.776.377.715.548.114.240
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Antibodies, Neoplasm".
Below are MeSH descriptors whose meaning is more specific than "Antibodies, Neoplasm".
This graph shows the total number of publications written about "Antibodies, Neoplasm" by people in this website by year, and whether "Antibodies, Neoplasm" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 0 | 2 | 2 |
| 1996 | 0 | 1 | 1 |
| 1998 | 0 | 2 | 2 |
| 2000 | 1 | 1 | 2 |
| 2003 | 1 | 0 | 1 |
| 2004 | 3 | 1 | 4 |
| 2005 | 2 | 2 | 4 |
| 2006 | 4 | 0 | 4 |
| 2007 | 3 | 1 | 4 |
| 2008 | 0 | 1 | 1 |
| 2009 | 5 | 1 | 6 |
| 2010 | 1 | 1 | 2 |
| 2011 | 1 | 0 | 1 |
| 2012 | 1 | 0 | 1 |
| 2013 | 1 | 0 | 1 |
| 2016 | 0 | 1 | 1 |
| 2019 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Antibodies, Neoplasm" by people in Profiles.
-
Targeted antibody and cytokine cancer immunotherapies through collagen affinity. Sci Transl Med. 2019 04 10; 11(487).
-
HLA superfamily assignment is a predictor of immune response to cancer testis antigens and survival in ovarian cancer. Gynecol Oncol. 2016 07; 142(1):158-162.
-
Engineered SIRPa variants as immunotherapeutic adjuvants to anticancer antibodies. Science. 2013 Jul 05; 341(6141):88-91.
-
Characterization and immunotherapeutic implications for a novel antibody targeting interleukin (IL)-13 receptor a2. J Biol Chem. 2012 Aug 31; 287(36):30215-27.
-
Alemtuzumab in allogeneic hematopoetic stem cell transplantation. Expert Opin Biol Ther. 2011 Aug; 11(8):1099-111.
-
Phase I study of dose-escalated busulfan with fludarabine and alemtuzumab as conditioning for allogeneic hematopoietic stem cell transplant: reduced clearance at high doses and occurrence of late sinusoidal obstruction syndrome/veno-occlusive disease. Leuk Lymphoma. 2010 Dec; 51(12):2240-9.
-
Consolidation therapy with subcutaneous alemtuzumab after fludarabine and rituximab induction therapy for previously untreated chronic lymphocytic leukemia: final analysis of CALGB 10101. J Clin Oncol. 2010 Oct 10; 28(29):4500-6.
-
Patterns and kinetics of T-cell chimerism after allo transplant with alemtuzumab-based conditioning: mixed chimerism protects from GVHD, but does not portend disease recurrence. Leuk Lymphoma. 2009 Nov; 50(11):1809-17.
-
Fludarabine followed by alemtuzumab consolidation for previously untreated chronic lymphocytic leukemia: final report of Cancer and Leukemia Group B study 19901. Leuk Lymphoma. 2009 Oct; 50(10):1589-96.
-
A human monoclonal antibody drug and target discovery platform for B-cell chronic lymphocytic leukemia based on allogeneic hematopoietic stem cell transplantation and phage display. Blood. 2009 Nov 12; 114(20):4494-502.